BLUE vs CRSP: bluebird bio vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
bluebird bio and CRISPR Therapeutics both compete in sickle cell disease with approved one-time gene treatments (Lyfgenia vs Casgevy), but CRISPR Therapeutics has a stronger commercial partner (Vertex) and a more robust balance sheet. bluebird has more approved indications but significantly weaker commercial execution and more fragile finances.
BLUE vs CRSP is a financially fragile gene therapy pioneer versus the CRISPR gene editing leader with Vertex commercial partnership — both compete in sickle cell disease, but CRISPR Therapeutics has superior financial strength, commercial backing, and technology breadth.
BLUE and CRSP are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- believe bluebird's three approved gene therapies will eventually find commercial traction
- want speculative exposure to a gene therapy pioneer at a deeply distressed valuation
- are comfortable with high execution risk, cash runway uncertainty, and commercial ramp challenges
- believe lentiviral vector gene therapy has advantages for specific indications vs CRISPR approaches
- prefer the CRISPR gene editing leader with Vertex commercial partnership for Casgevy
- want gene editing exposure with a more robust balance sheet and clinical pipeline
- value CRISPR's technology platform breadth across sickle cell, diabetes, and oncology
- prefer a lower-risk genetic medicine bet than bluebird's financially stressed situation
| Metric | BLUE | CRSP |
|---|---|---|
| AI scorei | N/A | 48.7 |
| AI ranki | N/A | #743 |
| Latest closei | N/A | $49.25 |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BLUE | CRSP |
|---|---|---|
| 1Y ago | N/A | $7.2K (-28.0%) started 2025-10-16 |
| 5Y ago | N/A | $5.12K (-48.8%) started 2021-10-18 |
| 10Y ago | N/A | $34.95K (+249.5%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BLUE | CRSP |
|---|---|---|
| Market capi | N/A | $5.44B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | -16.10 |
| Price/Salesi | 0.58 | N/A |
| EV/Revenuei | N/A | 292.23 |
| Analyst targeti | N/A | $87.56 |
| Target upsidei | N/A | +55.54% |
| Metric | BLUE | CRSP |
|---|---|---|
| Revenue growthi | N/A | 1041.40% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | -1611.75% |
| Operating margini | N/A | -1127.55% |
| Profit margini | N/A | 0.00% |
| ROIC proxyi | N/A | -26.10% |
| Return on equityi | N/A | -26.10% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.49 | 1.74 |
| Debt/equityi | N/A | 44.87 |
| Current ratioi | N/A | 17.85 |
| Quick ratioi | N/A | 17.79 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BLUE | CRSP |
|---|---|---|---|
| 1Y | Growthi | N/A | -28.03% |
| CAGRi | N/A | -28.04% | |
| Volatilityi | N/A | 58.17% | |
| Sharpe ratioi | N/A | -0.36 | |
| Sortino ratioi | N/A | -0.52 | |
| Max drawdowni | N/A | 40.06% | |
| Current drawdowni | N/A | 33.42% | |
| Avg drawdowni | N/A | 26.87% | |
| Ulcer Indexi | N/A | 27.64% | |
| Max daily dropi | N/A | 11.59% | |
| Max wkly dropi | N/A | 18.19% | |
| 5Y | Growthi | N/A | -48.81% |
| CAGRi | N/A | -12.55% | |
| Volatilityi | N/A | 60.95% | |
| Sharpe ratioi | N/A | 0.01 | |
| Sortino ratioi | N/A | 0.01 | |
| Max drawdowni | N/A | 68.81% | |
| Current drawdowni | N/A | 50.88% | |
| Avg drawdowni | N/A | 43.93% | |
| Ulcer Indexi | N/A | 45.40% | |
| Max daily dropi | N/A | 13.32% | |
| Max wkly dropi | N/A | 21.49% | |
| 10Y | Growthi | N/A | +249.54% |
| CAGRi | N/A | +13.34% | |
| Volatilityi | N/A | 63.96% | |
| Sharpe ratioi | N/A | 0.44 | |
| Sortino ratioi | N/A | 0.68 | |
| Max drawdowni | N/A | 85.11% | |
| Current drawdowni | N/A | 76.55% | |
| Avg drawdowni | N/A | 50.10% | |
| Ulcer Indexi | N/A | 56.56% | |
| Max daily dropi | N/A | 17.10% | |
| Max wkly dropi | N/A | 30.47% |
| Category | BLUE | CRSP |
|---|---|---|
| Company | bluebird bio, Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Biotechnology |
| Core business | Gene therapy company with three approved gene therapies: Zynteglo (beta-thalassemia), Lyfgenia (sickle cell disease), and Skysona (cerebral adrenoleukodystrophy). bluebird uses lentiviral vector delivery to correct disease-causing genetic mutations. | Gene editing company with Casgevy (the world's first approved CRISPR therapy for sickle cell and beta-thalassemia co-developed with Vertex) and a pipeline in diabetes and oncology. |
| Investor focus | Commercial ramp of Zynteglo and Lyfgenia, patient identification and treatment site expansion, reimbursement outcomes, and cash runway toward commercial sustainability. | Casgevy commercial adoption, pipeline advancement in diabetes (CTX112) and CAR-T oncology, and next-generation in vivo CRISPR delivery. |
- bluebird has three approved gene therapies — more regulatory approvals than most gene therapy companies
- Lyfgenia directly competes with Casgevy (CRISPR) for sickle cell patients — a validated market with proven payer acceptance
- Lentiviral vector delivery is a well-understood and clinically proven gene delivery approach
- Casgevy is co-commercialized with Vertex's large commercial infrastructure, giving CRSP a competitive advantage in sickle cell market access
- CRISPR-Cas9 is a more flexible gene editing platform than lentiviral vectors for future disease applications
- Strong balance sheet from Vertex milestone payments provides multi-year runway
- Commercial uptake has been extremely slow due to the high cost ($3M+) and complex patient identification process
- bluebird has faced repeated cash crises and has depended on equity issuance to fund operations
- Casgevy (CRISPR/Vertex) competes directly with Lyfgenia in sickle cell disease — a better-funded competitor
- Casgevy competes with bluebird's Lyfgenia — both treat sickle cell disease with similar one-time gene treatment approaches
- Casgevy's complex administration (bone marrow conditioning) limits treatment site capacity
- CRISPR's in vivo delivery for future programs remains technically unproven at commercial scale
Compare more than two at a time
This page is a fixed writeup on BLUE and CRSP. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside BLUE and CRSP, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.